Retro Biosciences Co-Founder Joe Betts-Lacroix, and the company's board member, Sandro Salsano from the Salsano Group talk to CNBC's Squawk Box Asia about the startup's bold bet to extend healthy human lifespan by another 10 years.
Breakdown
- Retro Biosciences is developing a drug targeting Alzheimer's disease, showing early efficacy and safety in preclinical studies. 11s
- OpenAI CEO Sam Altman is an early backer, having seeded the company with $180 million. 1m 19s
- The company is raising a $1 billion Series A round to advance its research and development. 2m 37s
- Investors highlight the founder's previous successes and the team's expertise as reasons for their support. 1m 46s
- There is growing momentum in AI-driven biotech, with increased interest from institutional investors. 4m 48s